NEOGAP Therapeutics AB
Pharmaceutical ManufacturingView the employees at
NEOGAP Therapeutics AB-
Andrea Salmén COO på NEOGAP Therapeutics AB
-
Greater Stockholm Metropolitan Area
-
Rising Star
Kelly D. Senior Scientist at NEOGAP Therapeutics-
Top 10%
Samuel Svensson CEO på NEOGAP Therapeutics AB-
Top 10%
Ola Nilsson Head of Neoantigen Production & Development på NEOGAP Therapeutics AB-
Top 10%
Alejandro Fernandez Woodbridge making NGS bioinformatics for the people...-
Stockholm, Stockholm County, Sweden
-
Top 5%
Overview
NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden. Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy.
-